Composite thymus peptide with immunoregulation function

Abstract

The invention relates to a composite thymus peptide injection with immunity regulation action, wherein the preparation is prepared from thymus peptide and thymus peptide alpha 1 according to optimum proportion through finite processes, the proportion of the preparation content by weight percent being thymus peptide : thymus peptide alpha 1 = 5-100mg : 0.1-5mg.

Description

field of invention [0001] The invention relates to a novel immunoregulatory drug, which is an immune auxiliary therapeutic drug for treating diseases such as viral hepatitis, tumor, skin disease, venereal disease and AIDS. Background of the invention [0002] Viral hepatitis and tumors are common and frequently occurring diseases in my country. my country is a high-incidence area for various hepatitis diseases. There are about 100 million hepatitis patients and hepatitis virus carriers. There are also about 2 million cancer patients in China. Hepatitis and cancer cause millions of deaths in China every year. At the same time, patients with skin diseases, venereal diseases and AIDS are also rapidly increasing at home and abroad. These diseases seriously threaten the life and health of human beings, and the harm to human beings is becoming more and more serious. [0003] Interferon + immunomodulator + antiviral drug is currently recognized as the most effective combined drug ...

AI Technical Summary

Problems solved by technology

[0006] With the extensive clinical application of thymosin and thymosin α1, while confirming the curative effect of the two products, it is also found that using a single component of thymosin α1 alone or using multiple components of thymosin in large quantities to regulate the body’s immunity is insufficient. : ① Thymosin has been used clinically for many years, and the therapeutic efficacy of using thymosin alone has been confirmed through years of clinical practice, but the active ingredient thymosin α1 contained in thymosin is too low (about 1%), and the content of thymosin has to be increased in order to improve the effect. Dosage, the therapeutic dose of thymosin increased from 5 mg per person per day at the beginning to 20 mg per person per day at present, or even 160 mg per person per day

Because thymosin is derived from animal organs, after increasing the dose, the increase in immunogenicity leads to a series of adverse reactions and increases the cost of patients

②Clinical practice has confirmed the reliability and immunomodulatory effect of using thymosin α1 alone, but only a few pharmaceutical companies produce thymosin α1, which is expensive, and the single component of thymosin α1 affects the therapeutic effect, which limits its wide clinical use